Drug Profile
CMX 020
Alternative Names: CMX-020Latest Information Update: 31 Aug 2022
Price :
$50
*
At a glance
- Originator Cmxtwenty
- Class Arachidonic acids; Non-opioid analgesics
- Mechanism of Action Adenosine A3 receptor modulators; Cannabinoid receptor CB1 modulators; Cannabinoid receptor CB2 modulators; Melatonin MT1 receptor modulators; Opioid delta receptor modulators; Opioid kappa receptor modulators; TRPV1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pain
Most Recent Events
- 26 Aug 2022 Cmxtwenty plans a follow-up clinical study of CMX 020 for pain linked to hip replacements (IV)
- 26 Aug 2022 Cmxtwenty plans study of CMX 020 in Pain (PO)
- 20 Mar 2022 Cmxtwenty plans to initiate a phase II POC study for pain associated with hip or knee replacement (Cmxtwenty pipeline, March 2022)